Biocubafarma Reports Scientific Advances in 2025

The Biocubafarma Business Group reported that during 2025 it executed more than 400 research projects, with significant results in drug development, sanitary registrations, and patents, despite economic difficulties, according to the newspaper Granma.

Santiago Dueñas Carrera, vice president of the entity, noted that more than one hundred projects were carried out in cooperation with national institutions, achieving 20 high-impact scientific-technological results, including the introduction of Sodium Enoxaparin into the Health system.

The list included the development of an animal biomodel for the study of metabolic syndrome, the sanitary registration of Sincronida for bovine reproduction, and the definitive approval of the monoclonal antibody Racotumomab as maintenance therapy in advanced lung cancer.

Transgenic sugarcane lines resistant to smut and rust were also obtained, in addition to nutritional supplements and vitamin complexes produced with domestic raw materials, such as Polivitsina and Lisinopril tablets with Hydrochlorothiazide.

In the clinical field, evidence was reported of the favorable effect of the drug Jusvinza in patients with Chikungunya sequelae, while the first clinical trial of the same drug for rheumatoid arthritis began in China.

Other contributions included preclinical models with zebrafish, registration of diagnostic systems such as Sumasignal Apoe and Umtest msud, and evidence of the therapeutic effects of the Neuralcim antibody in patients with Alzheimer-type amnesic syndrome and ataxia.

During the year, six new patent applications were submitted, 42 were granted abroad and seven in Cuba, and joint ventures were established in Vietnam, Italy, Russia, and Australia, with the objective of accelerating the introduction of biopharmaceutical products.

Collaboration with institutions in China remained a priority, and 178 scientific articles were published in international media, 86 of them in high-visibility journals.

In total, 42 new sanitary registrations were approved abroad, reflecting the international impact of the results achieved by Biocubafarma in 2025.